Key Highlights
- Revenue was USD 106.12 million against an estimate of USD 115.31 million and USD 107.8 million a year earlier.
- EPS of USD -1.03 compares with an estimate of USD 0.52, with a net loss of USD 73.9 million.
- Net changes in Fair Value of Equity and Long-Term Investments totaled USD 139.5 million, mainly tied to Armata.
- Cash and cash equivalents were USD 581.4 million, and the company repurchased USD 26.3 million of stock in the quarter.
Innoviva, Inc. (NASDAQ:INVA) reported third quarter Revenue of USD 106.12 million, against USD 107.8 million a year earlier and an estimate of USD 115.31 million. The quarter ended with a net loss of USD 73.9 million, or USD 1.03 per basic share, which the company attributed primarily to a decrease in the fair value of equity and long-term investments.
Results and the Investment Value Change
Income from operations was USD 42.2 million against USD 34.6 million, which management tied to higher U.S. net product sales, partly offset by higher operating expenses from expanding commercial activities. Net changes in the fair value of equity and long-term investments totaled USD 139.5 million, a decline primarily tied to the stock price of Armata at quarter end.
Strategic healthcare investments were valued at USD 535.5 million at September 30, 2026. That figure consists of USD 323.7 million invested in Armata, USD 179.9 million in other strategic equity and convertible Debt investments, and USD 31.9 million held by ISP Fund. Selling, general and administrative expenses were USD 37.0 million against USD 27.3 million, which the company linked to expanding its sales force.
Royalties and Product Sales
Gross Royalty revenue from GSK was USD 58.1 million, which the company described as stable. Net product sales were USD 49.4 million, made up of USD 43.3 million in U.S. net product sales and USD 6.1 million in sales outside the U.S. U.S. net product sales rose 45% from USD 29.9 million.
By product, GIAPREZA contributed USD 23.1 million, XACDURO USD 16.1 million and XERAVA USD 3.4 million. Total revenue was lower than a year earlier because of the timing of inventory sales to ex-U.S. partners and royalty revenue, which offset U.S. product growth.
NUZOLVENCE, approved by the FDA on December 12, 2025 for uncomplicated urogenital gonorrhea, is now commercially available in the U.S. Initial efforts focus on market access, distribution and dispensing infrastructure. The company also markets ZEVTERA, launched commercially in the third quarter of 2025 under a license from Basilea.
Cash, Debt and Capital Returns
Cash and cash equivalents were USD 581.4 million, with royalty and net product sales receivables of USD 102.1 million. Net cash provided by Operating Activities was USD 128.95 million over nine months, against USD 142.42 million. The company has one convertible note outstanding, with USD 261.0 million of principal due in March 2028.
Under its USD 125 million repurchase program, authorized in November 2025, the company repurchased 1,226,948 shares for USD 26.3 million in the quarter. Since inception it has repurchased 3,829,116 shares for USD 82.7 million.
Priorities Management Named
No numerical guidance accompanies the quarter. Management described its priorities as managing the respiratory royalty Assets partnered with GSK, commercializing its marketed products, developing product candidates and optimizing capital allocation. It said its cash is sufficient to meet debt service, operating needs and the repurchase program for at least the next 12 months.
Figures Worth Comparing
Revenue of USD 106.12 million sits alongside a net loss of USD 73.9 million, a USD 139.5 million investment fair value change and cash of USD 581.4 million. Stated reference points include the March 2028 Maturity of the USD 261.0 million convertible note and the USD 125 million repurchase authorization, of which USD 82.7 million has been used.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...